➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
Moodys
Boehringer Ingelheim
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 7,192,718

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,192,718
Title:Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof
Abstract: The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.
Inventor(s): Yamaguchi; Kyoji (Saitama, JP), Yasuda; Hisataka (Tochigi, JP), Nakagawa; Nobuaki (Tochigi, JP), Shima; Nobuyuki (Tochigi, JP), Kinosaki; Masahiko (Tochigi, JP), Tsuda; Eisuke (Tochigi, JP), Goto; Masaaki (Tochigi, JP), Yano; Kazuki (Tochigi, JP), Tomoyasu; Akihiro (Tochigi, JP), Kobayashi; Fumie (Tochigi, JP), Washida; Naohiro (Tochigi, JP), Takahashi; Ken (Tochigi, JP), Morinaga; Tomonori (Tochigi, JP), Higashio; Kanji (Saitama, JP)
Assignee: Sankyo Co. Ltd (Tokyo, JP)
Application Number:10/460,623
Patent Claims:see list of patent claims

Details for Patent 7,192,718

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Sankyo Co. Ltd (Tokyo, JP) 2017-04-15 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Sankyo Co. Ltd (Tokyo, JP) 2017-04-15 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Sankyo Co. Ltd (Tokyo, JP) 2017-04-15 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Sankyo Co. Ltd (Tokyo, JP) 2017-04-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Merck
Boehringer Ingelheim
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.